Real-world data confirm clinical value of Bayer's novel oral anticoagulant Xarelto in protecting patients against blood clots

Data from the real-world XAMOS study just published in the journal Thrombosis and Haemostasis reaffirms the benefits of oral, once-daily Xarelto® (rivaroxaban) in everyday clinical practice to prevent potentially deadly blood clots in adults following major orthopaedic surgery of the hip or knee. Outcomes from the 17,000-patient study show Xarelto provided a favourable benefit-risk profile with patients experiencing fewer thromboembolic events and comparable low major bleeds compared to conventional pharmacological thromboprophylaxis regimens (standard of care)...